Analysts Offer Insights on Healthcare Companies: Agilent (NYSE: A), Global Blood Therapeutics (NASDAQ: GBT) and La Jolla Pharma (NASDAQ: LJPC)

By Austin Angelo

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Agilent (AResearch Report), Global Blood Therapeutics (GBTResearch Report) and La Jolla Pharma (LJPCResearch Report).

Agilent (A)

Needham analyst Stephen Unger maintained a Buy rating on Agilent today and set a price target of $85.00. The company’s shares closed last Monday at $80.26, close to its 52-week high of $82.27.

According to TipRanks.com, Unger is a 4-star analyst with an average return of 16.5% and a 83.3% success rate. Unger covers the Healthcare sector, focusing on stocks such as Myriad Genetics, Thermo Fisher, and PerkinElmer.

Currently, the analyst consensus on Agilent is a Moderate Buy with an average price target of $68.50, representing a -13.8% downside. In a report issued on November 12, Credit Suisse also reiterated a Buy rating on the stock with a price target.

See today’s analyst top recommended stocks >>

Global Blood Therapeutics (GBT)

Cowen & Co. analyst Ritu Baral maintained a Buy rating on Global Blood Therapeutics today and set a price target of $83.00. The company’s shares closed last Monday at $59.95, close to its 52-week high of $64.94.

According to TipRanks.com, Baral is a 5-star analyst with an average return of 20.8% and a 50.1% success rate. Baral covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals, Madrigal Pharmaceuticals, and ACADIA Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Global Blood Therapeutics with a $94.38 average price target, implying a 65.0% upside from current levels. In a report issued on November 21, Cantor Fitzgerald also maintained a Buy rating on the stock with a $110.00 price target.

La Jolla Pharma (LJPC)

H.C. Wainwright analyst Edward White downgraded La Jolla Pharma to Hold today. The company’s shares closed last Monday at $2.59, close to its 52-week low of $2.41.

According to TipRanks.com, White is a 5-star analyst with an average return of 16.0% and a 52.4% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and TRACON Pharmaceuticals.

La Jolla Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $11.50, which is a 238.2% upside from current levels. In a report released yesterday, SunTrust Robinson also downgraded the stock to Hold with a $3.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.